Society of Hematologic Oncology 1st Soho Israel Meeting the 7th International Davidoff Conference 2023
Format: 2 videos + 1 pdf, size: 47.2 GB
Course Audience: hematologist, oncologist
Overview:
The 1st Soho – Israel Meeting | the 7th International Davidoff Conference
“State of the Art & Next Questions…”
May 3rd – May 4th 2023, ANU – Museum of the Jewish People, Tel Aviv University
An annual International Davidoff Conference has become a tradition for the past 6 years.
SOHO – The Society of Hematologic Oncology was established in 2012 by the MD Anderson Group. Since then, around 6,000 members from 110 countries have joined the society from around the globe.
SOHO’s mission is to expedite worldwide research and education by exchanging scientific information.
Prof. Hagop Kantarjian, chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center and Prof. Pia Raanani, the ambassador of SOHO to Israel, will launch this year a yearly SOHO – Israel meetings’ program to be merged with the traditional annual Davidoff Conference, entitled: THE 1st SOHO – ISRAEL MEETING & THE 7th INTERNATIONAL DAVIDOFF CONFERENCE – STATE OF THE ART & NEXT QUESTIONS…
The conference is scheduled for May 3th – 5th ,2023 with 2 Educational days at the ANU – Museum of the Jewish People Tel Aviv University, and 1 Round Tables discussions day at the Dan hotel, Tel-Aviv.
The 2023 meeting will focus on new advances and practical clinical applications in the field of hematologic malignancies. The speakers are a multidisciplinary group of internationally recognized experts that represent the spectrum of these diseases.
Alongside the conference, there will be an innovative exhibition of pharmaceutical and medical equipment companies. Guided tours of the ANU museum will be available as well.
As a hybrid event, THE 1st SOHO – ISRAEL MEETING & THE 7th INTERNATIONAL DAVIDOFF CONFERENCE – STATE OF THE ART & NEXT QUESTIONS…offers in-person presence for Israeli participants and virtual attendance options for international attendees.
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below
agenda (PDF Format)
May 3 (Video MP4 Format)
May 4 (Video MP4 Format)
- Detail:
May 3rd, 2023
08:00-08:45
08:45-09:30
Registration, Gathering and Exhibition
Opening Ceremony- Honored by the President of the State of Israel
His Excellency Mr. Isaac Herzog
Honored by the presence of the Davidoff Family
09:30-11:15
Session 1
Chairpersons: Dr. Ofir Wolach & Dr. Itai Levi
09:30-10:00- How I treat ALL at MD Anderson in 2023
Hagop Kantarjian, MD, MD Anderson, Houston, USA10:00-10:05 – Q&A
10:05-10:40 – Are we ready for risk-adapted therapy in CML Timothy Hughes, MD, SAHMRI Beat Cancer, University of Adelaide, Australia10:40-11:15 – Novel prediction models in cancer associated thrombosis Jeffrey I. Zwicker, MD,Memorial Sloan Kettering Cancer Center, NY, USA
Coffee Break
11:15-11:45
11:45-12:00
Greetings
12:00-13:45
Chairpersons: Dr. Avi Leader & Dr. Tamar Tadmor
12:00-12:35 – Personalized induction strategies for AML Gail J. Roboz, MD, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA12:35-13:10 – Updates in T cell lymphoma with focus on emerging cellular therapies
Swaminathan Padmanabhan Iyer, MD, MD Anderson, Houston, USA13:10-13:45- Present and future of molecular testing in CML Simona Soverini, Ph.D, Alma Mater Studiorum Universita di Bologna, Italy
13:45-15:00
Lunch Break & Guided museum tour
15:00-17:20
Session 3
Chairpersons: Dr. Anat Gafter- Gvili & Dr. Luliana Vaxman
15:00-15:35 – Acute lymphoblastic leukemia at a single base resolution Gidi Rechavi, MD, Ph.D, Sheba Cancer Research Center, Tel-Hashomer, Israel 15:35-16:10 – Moving towards personalized therapy for Hodgkin lymphoma Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, NY,USA 16:10-16:45 – When not to transplant in ALL? Elias Joseph Jabbour, MD, MD Anderson, Houston, USA 16:45-17:20- Should high risk smoldering myeloma be treated outside of a clinical trial? Morie Gertz, MD, Mayo Clinic, Rochester Minnesota, USA
17:20-17:30
Closing Remarks
May 4th, 2023
08:00-08:50
Registration, Gathering and Exhibition
08:50-10:45
Session 4
Chairperson: Dr. Tzila Zuckerman & Dr. Avichai Shimoni
08:50-09:00 – Opening Remarks
09:00-09:35 – HMA/VEN…and then?
Richard Stone, MD, Dana Farber, Boston, USA
09:35-10:10 – Dormancy as a mechanism of innate resistance to therapy in myeloid malignancies Michael Deininger, MD, Versiti, USA
10:10-10:45 – Ph+ ALL today
Robin Foa, MD, “Sapienza” University of Rome, Italy
10:45-11:15
Coffee Break
11:15-13:00
Session 5
Chairpersons: Dr. Merav Leiba & Dr. Nadav Sarid
11:15-11:50 – From broad to ultra targeted therapeutic approaches in CML: which one is best?
Delphine Rea, MD, Hôpital Saint Louis, Paris, France
11:50-12:25 – CML treatment discontinuation in clinical practice: how can we ameliorate its feasibility?
Giuseppe Saglio, MD, University of Turin, Italy
12:25-13:00- Lymphoma/cellular therapy
Loretta Nastoupil, MD, MD Anderson, Houston, USA
13:00-14:15
Lunch Break & Guided museum tour
14:15-17:20
Session 6
Chairpersons: Dr. Moshe Gatt & Dr. Ariel Aviv
14:15-14:50 – Anticoagulant-related bleeding in Cancer
Kristen Sanfilippo, MD, Washington University School of Medicine in St. Louis,USA
14:50-15:25 – T-cell lymphoma
Steve Horwitz, MD, Memorial Sloan Kettering Cancer Center NY, USA
15:25-16:00 – Advances and remaining challenges for patients with Follicular Lymphoma
Gilles Salles, MD, Memorial Sloan Kettering Cancer Center NY, USA
16:00-17:35 – Novel agents in CLL: better sequenced or combined
Jan Burger, MD, MD Anderson, Houston, USA
17:35-18:10 – The changing landscape of artificial intelligence applications in Hematology
Roni Shouval, MD, Memorial Sloan Kettering Cancer Center NY, USA
18:10-18:20
Closing Remarks